COLUMBUS, Ohio – About 150 professionals in the fields of neurology, neuro-oncology and neurological surgery are expected to attend the 8th Annual Neuro-Oncology Update hosted by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research, and jointly co-sponsored by the department of neurosurgery/ neuro-oncology at Johns Hopkins University Medical Center, the Istituto Besta in Milan, Italy, and the Semmes-Murphy Clinic in Memphis, Tenn. The event will be held Sept. 8-10 at the Hyatt on Capitol Square, 75 E. State St. in Columbus.
The conference will focus on bench research, clinical practice, and clinical research initiatives in the diagnosis and treatment of patients with brain and spinal cord tumors. Attendees will learn of innovations in treatment modalities and research initiatives for central nervous system tumors.
The target audience includes academic and private physicians in neurology, child neurology, neuro-oncology, neurological surgery, surgical oncology, medical oncology, musculoskeletal oncology and radiation oncology, along with clinical researchers, nurses and other healthcare professionals in these fields.
“The goal of this yearly update is to provide all members of the multi-disciplinary health care team access to innovations in treatment modalities and research initiatives for central nervous system tumors,” says Dr. E. Antonio Chiocca, who is one of the co-hosts of the event together with Dr. Alex Olivi from Johns Hopkins, Dr. Francesco Di Meco from Besta and Dr. Al Sills from Semmes-Murphy. “We want to improve overall patient care and patient outcomes.”
For more information, visit http://www.osuccc.osu.edu/neuro-onc/.
The Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute is one of only 40 Comprehensive Cancer Centers in the United States designated by the National Cancer Institute. Ranked by U.S. News & World Report among the top 20 cancer hospitals in the nation, The James is the 180-bed adult patient-care component of the cancer program at The Ohio State University. The OSUCCC-James is one of only five centers in the country approved by the NCI to conduct both Phase I and Phase II clinical trials.# # #
Medical Center Communications